N-acetylgalactosamine 4-sulfatase
Phase 3Protein / enzyme
BioMarin PharmaceuticalN-acetylgalactosamine 4-sulfatase is one of 26 small molecule programs targeting Mucopolysaccharidosis. It is currently in Phase 3.
1
Indications
4
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Mucopolysaccharidosis
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Trexall
Alnylam PharmaceuticalsApproved
Neoral
NovartisApproved
Imuran
LLegacy Health System
Approved
Immunoglobulin
SanofiApproved
BMN 333
BioMarin PharmaceuticalPhase 3
ELAPRASE
TakedaApproved
ELAPRASE
TakedaPhase 3
Humira
CCelltrion
Phase 2
Genotropin
EMD SeronoPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
MPS VI2 trials
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company